Chlorhexidine mouthwash for the prevention of alveolar osteitis after oral surgery
ISRCTN | ISRCTN14646628 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN14646628 |
Secondary identifying numbers | N/A |
- Submission date
- 13/08/2016
- Registration date
- 16/08/2016
- Last edited
- 22/01/2019
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Oral Health
Plain English summary of protocol
Background and study aims
Alveolar osteitis (AO) is the most common complication of tooth removal. It occurs when a blood clot fails to develop in the tooth socket, or if the blood clot becomes dislodged or disappears. The empty socket causes severe pain, headaches, fever, and paresthesia (pins and needles). Today, treatments are focused on managing the symptoms and these are not very effective, highlighting the importance of preventing the development of AO. The aim of this study is to assess the effectiveness of chlorhexidine mouthwash after tooth extraction in patients who are at risk of developing AO (previous surgical site infection, traumatic extraction, and tobacco smoking).
Who can participate?
Adults who have undergone tooth extractions and are at risk of developing AO
What does the study involve?
After the tooth extraction, participants are randomly allocated to use either chlorhexidine mouthwash or sterile water for 30 seconds, twice daily for 7 days, starting 24 hours after extraction. After 7 days participants are followed-up to check whether they have developed AO.
What are the possible benefits and risks of participating?
Chlorhexidine mouthwash may reduce the chance of developing AO. The only risk is hypersensitivity (allergic reaction) to chlorhexidine.
Where is the study run from?
Valdivia and Panguipulli, Región de Los Ríos, Chile
When is the study starting and how long is it expected to run for?
June 2012 to December 2015
Who is the main contact?
Dr Diego Halabi
diego.halabi@uach.cl
Contact information
Scientific
Edificio de Ciencias Biomedicas
Facultad de Medicina
Isla Teja
Valdivia
5090000
Chile
0000-0002-1474-8066 | |
Phone | +56 (0)63 2293928 |
diego.halabi@uach.cl |
Study information
Study design | Prospective stratified parallel randomized double-blind placebo-controlled clinical trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Prevention |
Participant information sheet | Not available in web format, please use the contact details to request a patient information sheet |
Scientific title | Chlorhexidine 0.12% mouthwash for the prevention of alveolar osteitis after oral surgery: a double-blind randomized clinical trial |
Study acronym | ChAOP (Chlorhexidine for Alveolar Osteitis Prevention) |
Study objectives | Chlorhexidine 0.12% mouthwash is better than placebo at preventing alveolar osteitis after oral surgery. |
Ethics approval(s) | Research Ethic Committee of Health Community Service of Valdivia, Chile, 22/03/2013, ORD.: Nº 073 |
Health condition(s) or problem(s) studied | Alveolar osteitis (dry socket) |
Intervention | Treatment: consisted of a mouthwash with 15 mL chlorhexidine 0.12% (Oralgene® Mouthwash 0.12%, Maver, Chile) for 30 seconds, twice daily for 7 days, starting 24 hours after extraction. Placebo: Sterile water, with the same indications for use as chlorhexidine. Chlorhexidine and placebo were stored in similar brown plastic bottles, and instructions were given orally and in writing to each participant. Patients were randomly allocated to the Chlorhexidine or Placebo group, matched by risk factors, and seven groups were formed with the following possible combinations: smoker, previous infection, traumatic extraction, smoker + previous infection, smoker + traumatic extraction, previous infection + traumatic extraction, previous infection, traumatic extraction. To avoid the risk of having more patients in a group, we stored black envelopes in a box containing a paper with the letter C for chlorhexidine or P for placebo (half of each). For each patient who was assigned to a group, the subsequent patient who arrived with the same risk factors was matched to the opposite group, and the respective envelope was discarded (to ensure homogeneity of groups). |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase IV |
Drug / device / biological / vaccine name(s) | Chlorhexidine 0.12% mouthwash |
Primary outcome measure | Positive diagnosis of alveolar osteitis was identified in patients with the following two characteristics (both variables must be present): 1. Increasing postoperative pain intensity for 4 days within and around the socket: We asked as a dichotomous variable: yes or no. (AO presents with severe pain, therefore, this variable is easily detectable) 2. Total or partial breakdown of the blood clot in the socket with or without bone exposure: like pain, this variable is easy detectable by clinical examination, the clot should completely cover the socket for proper healing The primary outcome was measured seven days after dental surgery |
Secondary outcome measures | N/A |
Overall study start date | 01/06/2012 |
Completion date | 27/12/2015 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 744 |
Key inclusion criteria | Patients with clinical indications for tooth extraction, and who presented at least one of the following risk factors for developing alveolar osteitis: 1. Tobacco smoker (consumption of ≥ 5 cigarettes 24 hrs before extraction) 2. Previous surgical site infection (clinical diagnosis of chronic periodontitis, acute periodontal conditions, apical periodontitis, pericoronitis, fungal infections, or dental pulp gangrene) 3. Traumatic extraction (lifting a flap, use of elevators for > 4 min, and/or rotary instruments) |
Key exclusion criteria | 1. Patients requiring extraction in the operating theater 2. Patients living in rural areas who manifested difficulty in returning for follow-up 3. Patients allergic to chlorhexidine 4. Patients under antimicrobial therapy, antibiotic prophylaxis, or antibiotics therapy after extraction |
Date of first enrolment | 01/04/2013 |
Date of final enrolment | 27/12/2015 |
Locations
Countries of recruitment
- Chile
Study participating centres
Valdivia
5090000
Chile
Panguipulli, Valdivia
5210000
Chile
Sponsor information
University/education
Campus Isla Teja S/N
Valdivia
5090000
Chile
Website | http://www.uach.cl |
---|---|
https://ror.org/029ycp228 |
Funders
Funder type
Other
No information available
Results and Publications
Intention to publish date | 27/12/2016 |
---|---|
Individual participant data (IPD) Intention to share | Yes |
IPD sharing plan summary | Available on request |
Publication and dissemination plan | We are preparing the manuscript for publication before this year ends (2016) |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 01/09/2018 | 22/01/2019 | Yes | No |
Editorial Notes
22/01/2019: Publication reference added